SEC Form 4 · accession 0001209191-15-011613
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jacqualyn A Fouse
Officer — see remarks
Period of report
Feb 6, 2015
Accepted (ET)
Feb 10, 2015 · 6:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2015 | A | 812 | $0.00 | A | 44,618 | D | |
| Common Stock | Feb 6, 2015 | F | 812 | $118.75 | D | 43,806 | D | |
| Common Stock | holding | — | — | — | 1,135 | I | 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Phantom StockF1,F2,F3 | — | Feb 6, 2015 | A | 34,660 | A | — | — | Common Stock | 34,660 | 34,660 | D |
Explanation of responses
- F1The reporting person was awarded 35,472 shares of common stock pursuant to the 2012-2014 Long Term Incentive Plan under the Celgene Corporation 2008 Stock Incentive Plan (Amended and Restated as of April 17, 2013). The reporting person deferred the receipt of 34,660 shares of common stock and received instead 34,660 shares of phantom stock pursuant to the Celgene Corporation 2005 Deferred Compensation Plan.
- F2Each share of phantom stock represents a right to receive one share of common stock.
- F3The phantom stock becomes payable six months following the reporting person's termination of employment with Celgene Corporation.
Remarks
President Hematology and Oncology